Compounds > N-(3-cyano-2-thiophenyl)-2-[(1-methyl-2-imidazolyl)thio]acetamide

Page last updated: 2024-12-10

N-(3-cyano-2-thiophenyl)-2-[(1-methyl-2-imidazolyl)thio]acetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	2997683
CHEMBL ID	1382247
CHEBI ID	105379

Synonyms (12)

Synonym
MLS000053946
smr000062346
STK473764
n-(3-cyanothiophen-2-yl)-2-[(1-methyl-1h-imidazol-2-yl)sulfanyl]acetamide
CHEBI:105379
AKOS001038287
n-(3-cyanothiophen-2-yl)-2-(1-methylimidazol-2-yl)sulfanylacetamide
HMS2309G21
CHEMBL1382247
n-(3-cyano-2-thiophenyl)-2-[(1-methyl-2-imidazolyl)thio]acetamide
Q27183104
Z18499049

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
aromatic amide	An amide in which the amide linkage is bonded directly to an aromatic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (18)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	79.4328	0.0447	17.8581	100.0000	AID485294
Chain A, HADH2 protein	Homo sapiens (human)	Potency	31.6228	0.0251	20.2376	39.8107	AID893
Chain B, HADH2 protein	Homo sapiens (human)	Potency	31.6228	0.0251	20.2376	39.8107	AID893
ClpP	Bacillus subtilis	Potency	3.5481	1.9953	22.6730	39.8107	AID651965
phosphopantetheinyl transferase	Bacillus subtilis	Potency	79.4328	0.1413	37.9142	100.0000	AID1490
Microtubule-associated protein tau	Homo sapiens (human)	Potency	22.3872	0.1800	13.5574	39.8107	AID1460
Smad3	Homo sapiens (human)	Potency	0.7079	0.0052	7.8098	29.0929	AID588855
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	25.1189	0.0112	12.4002	100.0000	AID1030
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	0.5623	0.0355	20.9770	89.1251	AID504332
importin subunit beta-1 isoform 1	Homo sapiens (human)	Potency	31.6228	5.8048	36.1306	65.1308	AID540263
DNA polymerase beta	Homo sapiens (human)	Potency	31.6228	0.0224	21.0102	89.1251	AID485314
snurportin-1	Homo sapiens (human)	Potency	31.6228	5.8048	36.1306	65.1308	AID540263
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)	Potency	42.5615	0.4256	12.0591	28.1838	AID504891
DNA polymerase eta isoform 1	Homo sapiens (human)	Potency	12.5893	0.1000	28.9256	213.3130	AID588591
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	15.8489	0.0501	27.0736	89.1251	AID588590
lethal(3)malignant brain tumor-like protein 1 isoform I	Homo sapiens (human)	Potency	31.6228	0.0752	15.2253	39.8107	AID485360
DNA polymerase kappa isoform 1	Homo sapiens (human)	Potency	89.1251	0.0316	22.3146	100.0000	AID588579
Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)	Potency	15.8489	6.3096	15.3445	35.4813	AID743286
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Process	via Protein(s)	Taxonomy
regulation of autophagy	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
megakaryocyte development	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
negative regulation of insulin receptor signaling pathway	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
autophagosome-lysosome fusion	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
vesicle-mediated cholesterol transport	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate biosynthetic process	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
positive regulation of autophagosome assembly	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Process	via Protein(s)	Taxonomy
protein binding	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
ATP binding	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 5-kinase activity	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
1-phosphatidylinositol-5-phosphate 4-kinase activity	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
protein homodimerization activity	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Process	via Protein(s)	Taxonomy
photoreceptor outer segment	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
photoreceptor inner segment	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
nucleoplasm	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
lysosome	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
autophagosome	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
cytosol	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay ID	Title	Year	Journal	Article
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	3 (60.00)	24.3611
2020's	1 (20.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.56 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.36 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Condition	Indicated	Relationship Strength	Studies	Trials
Innate Inflammatory Response [description not available]	0	2.05	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.05	1	0